Protective role of anti-idiotypic antibodies in autoimmunity – Lessons for type 1 diabetes

References

• Kunkel HG, Mannik M, Williams RC. Individual Antigenic Specificity of Isolated Antibodies. Science. 1963; 140:1218–1219.
   PubMed Web of Science ®Google Scholar
• Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris). 1974; 125C:373–389.
   PubMedGoogle Scholar
• Jerne NK. Clonal selection in a lymphocyte network. Soc Gen Physiol Ser. 1974; 29:39–48.
   Google Scholar
• Jerne NK. The immune system. Sci Am. 1973; 229:52–60.
   PubMed Web of Science ®Google Scholar
• Kim BS. Mechanisms of idiotype suppression: role of anti-idiotype antibody. Surv Immunol Res. 1982; 1:126–132.
   Google Scholar
• Rodkey LS. Autoregulation of immune responses via idiotype network interactions. Microbiol Rev. 1980; 44:631–659.
   Google Scholar
• Tzioufas AG, Routsias JG. Idiotype, anti-idiotype network of autoantibodies. Pathogenetic considerations and clinical application. Autoimmun Rev. 2010; 9:631–633.
   Google Scholar
• Behn U. Idiotypic networks: toward a renaissance?. Immunol Rev. 2007; 216:142–152.
   Google Scholar
• Coutinho A. Will the idiotypic network help to solve natural tolerance?. Trends Immunol. 2003; 24:53–54.
   Google Scholar
• Allen CD, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007; 27:190–202.
   PubMed Web of Science ®Google Scholar
• Clark LA, Ganesan S, Papp S, van Vlijmen HW. Trends in antibody sequence changes during the somatic hypermutation process. J Immunol. 2006; 177:333–340.
   PubMed Web of Science ®Google Scholar
• Bogen B, Ruffini P. Review: to what extent are T cells tolerant to immunoglobulin variable regions?. Scand J Immunol. 2009; 70:526–530.
   PubMed Web of Science ®Google Scholar
• Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol. 1986; 16:1373–1378.
   PubMed Web of Science ®Google Scholar
• Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol. 1996; 157:1037–1046.
   PubMed Web of Science ®Google Scholar
• Janeway CAJr, Sakato N, Eisen HN. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA. 1975; 72:2357–2360.
   PubMed Web of Science ®Google Scholar
• Jerne NK, Roland J, Cazenave PA. Recurrent idiotopes and internal images. Embo J. 1982; 1:243–247.
   PubMed Web of Science ®Google Scholar
• Schrater AF, Goidl EA, Thorbecke GJ, Siskind GW. Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. III. Absence in nu/nu mice: evidence for T-cell dependence of the anti-idiotypic-antibody response. J Exp Med. 1979; 150:808–817.
   Google Scholar
• Papamattheou MG, Routsias JG, Karagouni EE, Sakarellos C, Sakarellos-Daitsiotis M, Moutsopoulos HM, Tzioufas AG, Dotsika EN. T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289–308aa of La/SSB autoantigen in non-autoimmune mice. Clin Exp Immunol. 2004; 135:416–426.
   Google Scholar
• Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA. 1989; 86:282–286.
   PubMed Web of Science ®Google Scholar
• King CA, Wills MR, Hamblin TJ, Stevenson FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol. 1993; 147:411–424.
   PubMed Web of Science ®Google Scholar
• Tite JP, Kaye J, Saizawa KM, Ming J, Katz ME, Smith LA, Janeway CAJr. Direct interactions between B and T lymphocytes bearing complementary receptors. J Exp Med. 1986; 163:189–202.
   Google Scholar
• Reitan SK, Hannestad K. The primary IgM antibody repertoire: a source of potent idiotype immunogens. Eur J Immunol. 2001; 31:2143–2153.
   Google Scholar
• Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B. The cellular mechanism by which complementary Id(+) and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol. 2010; 55:515–522.
   Google Scholar
• Snyder CM, Aviszus K, Heiser RA, Tonkin DR, Guth AM, Wysocki LJ. Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. J Exp Med. 2004; 200:1–11.
   PubMedGoogle Scholar
• Munthe LA, Corthay A, Os A, Zangani M, Bogen B. Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol. 2005; 175:2391–2400.
   PubMed Web of Science ®Google Scholar
• Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell. 1991; 64:767–776.
   PubMed Web of Science ®Google Scholar
• Munthe LA, Kyte JA, Bogen B. Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. Eur J Immunol. 1999; 29:4043–4052.
   PubMed Web of Science ®Google Scholar
• Nayak R, Mitra-Kaushik S, Shaila MS. Perpetuation of immunological memory: a relay hypothesis. Immunology. 2001; 102:387–395.
   PubMedGoogle Scholar
• Vani J, Nayak R, Shaila MS. Maintenance of antigen-specific immunological memory through variable regions of heavy and light chains of anti-idiotypic antibody. Immunology. 2007; 120:486–496.
   Google Scholar
• Geha RS. Presence of circulating anti-idiotype-bearing cells after booster immunization with tetanus toxoid (TT) and inhibition of anti-TT antibody synthesis by auto-anti-idiotypic antibody. J Immunol. 1983; 130:1634–1639.
   PubMedGoogle Scholar
• Sapir T, Shoenfeld Y. Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol. 2005; 29:185–199.
   PubMedGoogle Scholar
• Wallmann J, Pali-Scholl I, Jensen-Jarolim E. Anti-Ids in Allergy: Timeliness of a Classic Concept. World Allergy Organiz J. 2010; 3:195–201.
   PubMedGoogle Scholar
• Kojima K, Matsuyama T, Tanaka H. Suppression of in vitro human antithyroglobulin antibody secretion by private and cross-reactive anti-idiotypic antibodies. Clin Immunol Immunopathol. 1986; 39:337–344.
   Google Scholar
• Horsfall AC, Mumford PA, Venables PJ, Maini RN. Anti-idiotypic induced suppression of Sjogren's syndrome associated anti-La autoantibody secretion in vitro. Clin Exp Immunol. 1988; 71:62–66.
   PubMedGoogle Scholar
• Koide J, Takeuchi T, Hosono O, Takano M, Abe T. Suppression of in vitro production of anti-U1-ribonucleoprotein antibody by monoclonal anti-idiotypic antibody to anti-U1-ribonucleoprotein antibody. Scand J Immunol. 1988; 28:687–696.
   Google Scholar
• Bolland S, Pearse RN, Kurosaki T, Ravetch JV. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity. 1998; 8:509–516.
   PubMed Web of Science ®Google Scholar
• Liu Q, Oliveira-Dos-Santos AJ, Mariathasan S, Bouchard D, Jones J, Sarao R, Kozieradzki I, Ohashi PS, Penninger JM, Dumont DJ. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J Exp Med. 1998; 188:1333–1342.
   PubMed Web of Science ®Google Scholar
• Brauweiler AM, Cambier JC. Autonomous SHIP-dependent FcgammaR signaling in pre-B cells leads to inhibition of cell migration and induction of cell death. Immunol Lett. 2004; 92:75–81.
   PubMedGoogle Scholar
• Ashman RF, Peckham D, Stunz LL. Fc receptor off-signal in the B cell involves apoptosis. J Immunol. 1996; 157:5–11.
   PubMed Web of Science ®Google Scholar
• Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002; 2:580–592.
   PubMed Web of Science ®Google Scholar
• Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999; 189:179–185.
   PubMed Web of Science ®Google Scholar
• Nakamura A, Yuasa T, Ujike A, Ono M, Nukiwa T, Ravetch JV, Takai T. Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J Exp Med. 2000; 191:899–906.
   PubMed Web of Science ®Google Scholar
• Su K, Yang H, Li X, Gibson AW, Cafardi JM, Zhou T, Edberg JC, Kimberly RP. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol. 2007; 178:3272–3280.
   PubMed Web of Science ®Google Scholar
• Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lunemann JD. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA. 2009; 106:4788–4792.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345:747–755.
   PubMed Web of Science ®Google Scholar
• Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev. 1989; 110:135–149.
   PubMed Web of Science ®Google Scholar
• Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007; 27:233–245.
   PubMed Web of Science ®Google Scholar
• Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991; 83:298–303.
   PubMed Web of Science ®Google Scholar
• Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunol. 1991; 11:291–295.
   PubMed Web of Science ®Google Scholar
• Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990; 85:620–625.
   PubMed Web of Science ®Google Scholar
• Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun. 1990; 3:547–557.
   Google Scholar
• Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 1989; 74:2414–2417.
   PubMed Web of Science ®Google Scholar
• Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC. Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction. Ann NY Acad Sci. 2008; 1132:244–248.
   Google Scholar
• Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev. 2011; 10:311–316.
   PubMed Web of Science ®Google Scholar
• Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984; 2:765–768.
   PubMed Web of Science ®Google Scholar
• Gilles JG, Grailly SC, De Maeyer M, Jacquemin MG, VanderElst LP, Saint-Remy JM. In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood. 2004; 103:2617–2623.
   Google Scholar
• Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum. 2000; 43:1647–1654.
   PubMed Web of Science ®Google Scholar
• Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology. 2002; 123:1144–1150.
   PubMed Web of Science ®Google Scholar
• Cavill D, Waterman SA, Gordon TP. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission. Arthritis Rheum. 2003; 48:3597–3602.
   PubMed Web of Science ®Google Scholar
• Dalakas M. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997; 126:721–730.
   PubMed Web of Science ®Google Scholar
• Liblau R, Gajdos P, Bustarret FA, el Habib R, Bach JF, Morel E. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991; 11:128–131.
   PubMedGoogle Scholar
• Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996; 47:678–683.
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 1:1228–1231.
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network. Clin Exp Rheumatol. 1996; 14 Suppl 15: S9–S15.
   Google Scholar
• Abdou NI, Suenaga R, Hatfield M, Evans M, Hassanein KM. Antiidiotypic antibodies against anti-DNA antibodies in sera of families of lupus patients. J Clin Immunol. 1989; 9:16–21.
   PubMed Web of Science ®Google Scholar
• Abdou NI, Wall H, Lindsley HB, Halsey JF, Suzuki T. Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest. 1981; 67:1297–1304.
   PubMed Web of Science ®Google Scholar
• Taniguchi O, Chia DS, Barnett EV. Auto-anti-anti-DNA antibodies from SLE patients and normals. J Rheumatol. 1984; 11:291–297.
   PubMed Web of Science ®Google Scholar
• Zouali M, Eyquem A. Expression of anti-idiotypic clones against auto-anti-DNA antibodies in normal individuals. Cell Immunol. 1983; 76:137–147.
   PubMed Web of Science ®Google Scholar
• Williams WM, Isenberg DA. Naturally occurring anti-idiotypic antibodies reactive with anti-DNA antibodies in systemic lupus erythematosus. Lupus. 1998; 7:164–175.
   PubMed Web of Science ®Google Scholar
• Silvestris F, Bankhurst AD, Searles RP, Williams RCJr. Studies of anti-F(ab')2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis Rheum. 1984; 27:1387–1396.
   PubMed Web of Science ®Google Scholar
• Williams RCJr, Malone CC, Huffman GR, Silvestris F, Croker BP, Ayoub EM, Massengill S. Active systemic lupus erythematosus is associated with depletion of the natural generic anti-idiotype (anti-F(ab')2) system. J Rheumatol. 1995; 22:1075–1085.
   PubMed Web of Science ®Google Scholar
• Routsias JG, Touloupi E, Dotsika E, Moulia A, Tsikaris V, Sakarellos C, Sakarellos-Daitsiotis M, Moutsopoulos HM, Tzioufas AG. Unmasking the anti-La/SSB response in sera from patients with Sjogren's syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Mol Med. 2002; 8:293–305.
   Google Scholar
• Weisbart RH, Noritake DT, Wong AL, Chan G, Kacena A, Colburn KK. A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus. J Immunol. 1990; 144:2653–2658.
   PubMed Web of Science ®Google Scholar
• Spertini F, Leimgruber A, Morel B, Khazaeli MB, Yamamoto K, Dayer JM, Weisbart RH, Lee ML. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol. 1999; 26:2602–2608.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Shoenfeld Y, Madaio MP, Rauch J, Reichlin M, Stollar BD, Schwartz RS. Anti-DNA antibody idiotypes in systemic lupus erythematosus. Lancet. 1984; 2:417–422.
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Bellisai F, Sebastiani GD, Morozzi G, Marcolongo R, Houssiau F, Cervera R, Levy Y, George J, Sherer Y, . Association of 16/6 and SA1 anti-DNA idiotypes with anticardiolipin antibodies and clinical manifestations in a large cohort of SLE patients. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998; 16:717–720.
   Google Scholar
• Blank M, Manosroi J, Tomer Y, Manosroi A, Kopolovic J, Charcon-Polak S, Shoenfeld Y. Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol. 1994; 98:434–441.
   PubMedGoogle Scholar
• Pan ZJ, Anderson CJ, Stafford HA. Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest. 1998; 102:215–222.
   PubMed Web of Science ®Google Scholar
• Stafford HA, Anderson CJ, Reichlin M. Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J Immunol. 1995; 155:2754–2761.
   PubMed Web of Science ®Google Scholar
• Anderson CJ, Neas BR, Pan Z, Taylor-Albert E, Reichlin M, Stafford HA. The presence of masked antiribosomal P autoantibodies in healthy children. Arthritis Rheum. 1998; 41:33–40.
   Google Scholar
• Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG. Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum. 2006; 54:2228–2234.
   Google Scholar
• Sikorska HM. Anti-thyroglobulin anti-idiotypic antibodies in sera of patients with Hashimoto's thyroiditis and Graves' disease. J Immunol. 1986; 137:3786–3795.
   PubMedGoogle Scholar
• Tandon N, Jayne DR, McGregor AM, Weetman AP. Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity. J Autoimmun. 1992; 5:557–570.
   PubMed Web of Science ®Google Scholar
• Paschke R, Teuber J, Enger I, Schmeidl R, Schwedes U, Usadel KH. Evidence for a role of anti-idiotypic antibodies in the induction of remission in Graves' disease. J Autoimmun. 1990; 3:441–448.
   Google Scholar
• Balazs C, Molnar I. In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease. Acta Microbiol Immunol Hung. 1995; 42:163–169.
   PubMedGoogle Scholar
• Tada H, Izumi Y, Watanabe Y, Takano T, Fukata S, Kuma K, Hidaka Y, Amino N. Blocking type anti-tSH receptor antibodies detected by radioreceptor assay in Graves' disease. Endocr J. 2001; 48:703–710.
   Google Scholar
• Kohler H, Kaveri S, Kieber-Emmons T, Morrow WJ, Muller S, Raychaudhuri S. Idiotypic networks and nature of molecular mimicry: an overview. Meth Enzymol. 1989; 178:3–35.
   PubMed Web of Science ®Google Scholar
• Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, Pennington CR, Rowley MJ, Christie MR, Banga JP, Hampe CS. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA. 2008; 105:5471–5476.
   PubMed Web of Science ®Google Scholar
• Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem. 2011; 57:168–175.
   PubMedGoogle Scholar
• Reijonen H, Daniels TL, Lernmark A, Nepom GT. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes. 2000; 49:1621–1626.
   PubMed Web of Science ®Google Scholar
• Banga JP, Moore JK, Duhindan N, Madec AM, Van Endert PM, Orgiazzi J, Endl J. Modulation of antigen presentation by autoreactive B cell clones specific for GAD65 from a type I diabetic patient. Clin Exp Immunol. 2004; 135:74–84.
   Google Scholar
• Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol. 2002; 169:665–672.
   Google Scholar
• Panto F, Giordano C, Amato MP, Pugliese A, Donatelli M, D'Acquisto G, Galluzzo A. The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients. J Autoimmun. 1990; 3:587–592.
   Google Scholar
• Colagiuri S, Leong GM, Thayer Z, Antony G, Dwyer JM, Kidson W, Wakefield D. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol. 1996; 14 Suppl 15: S93–S97.
   Google Scholar
• Pocecco M, De Campo C, Cantoni L, Tedesco F, Panizon F. Effect of high doses intravenous IgG in newly diagnosed diabetic children. Helv Paediatr Acta. 1987; 42:289–295.
   PubMedGoogle Scholar
• Heinze E, Thon A, Vetter U, Gaedicke G, Zuppinger K. Gamma-globulin therapy in 6 newly diagnosed diabetic children. Acta Paediatr Scand. 1985; 74:605–606.
   Google Scholar
• Urakami T, Hanaoka Y, Fujita H, Kitagawa T. High-dose gammaglobulin therapy in six children with newly diagnosed insulin-dependent diabetes mellitus. Acta Paediatr Jpn. 1987; 29:355–360.
   Google Scholar
• Heinze E. Immunoglobulins in children with autoimmune diabetes mellitus. Clin Exp Rheumatol. 1996; 14 Suppl 15: S99–102.
   Google Scholar
• Casiglia D, Giardina E, Triolo G. IgG auto-anti-idiotype antibodies against antibody to insulin in insulin-dependent (type 1) diabetes mellitus. Detection by capture enzyme linked immunosorbent assay (ELISA) and relationship with anti-insulin antibody levels. Diabetes Res. 1991; 16:181–184.
   Google Scholar
• Elias D, Bone AJ, Baird JD, Cooke A, Cohen IR. Insulin-mimicking anti-idiotypic antibodies in development of spontaneous autoimmune diabetes in BB/E rats. Diabetes. 1990; 39:1467–1471.
   Google Scholar
• Brown TJ, Christie MR. Detection of a serum factor that blocks antibody binding to glutamate decarboxylase. Diabetologia. 1993; Suppl 1:A92 (Abstr.).
   Google Scholar
• Hall TR, Bogdani M, Leboeuf RC, Kirk EA, Maziarz M, Banga JP, Oak S, Pennington CA, Hampe CS. Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology. 2008; 123:547–554.
   PubMed Web of Science ®Google Scholar
• Ortqvist E, Brooks-Worrell B, Lynch K, Radtke J, Bekris LM, Kockum I, Agardh CD, Cilio CM, Lethagen AL, Persson B, . Changes in GAD65Ab-specific antiidiotypic antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity. J Clin Endocrinol Metab. 2010; 95:E310–E318.
   Web of Science ®Google Scholar
• Haller MJ, Atkinson MA, Schatz DA. Efforts to prevent and halt autoimmune beta cell destruction. Endocrinol Metab Clin North Am. 2010; 39:527–539.
   Google Scholar
• Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Compl. 2005; 19:238–246.
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Casas R, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson N, Åman J, Örtqvist E, . The Swedish GAD-vaccination Trial: outcomes of a phase II safety and efficacy trial with DiamydTM for preservation of beta cell function in children with T1D. Diabetologia. 2006; 49:1–755.
   Google Scholar
• Ohi H, Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol. 1994; 95:316–321.
   Google Scholar
• Spitzer RE, Stitzel AE, Tsokos GC. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase. Clin Immunol Immunopathol. 1990; 57:19–31.
   Google Scholar
• Spitzer RE, Stitzel AE, Tsokos GC. Study of the idiotypic response to autoantibody to the alternative pathway C3/C5 convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. Clin Immunol Immunopathol. 1992; 62:291–294.
   PubMedGoogle Scholar
• Nardi M, Karpatkin S. Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. J Exp Med. 2000; 191:2093–2100.
   PubMedGoogle Scholar
• Abrams CS, Ruggeri ZM, Taub R, Hoxie JA, Nagaswami C, Weisel JW, Shattil SJ. Anti-idiotypic antibodies against an antibody to the platelet glycoprotein (GP) IIb-IIIa complex mimic GP IIb-IIIa by recognizing fibrinogen. J Biol Chem. 1992; 267:2775–2785.
   Google Scholar
• Mehta YS, Ghosh K, Badakere SS, Pathare AV, Mohanty D. Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura. J Lab Clin Med. 2003; 142:113–120.
   PubMed Web of Science ®Google Scholar
• Csernok E, Muller A, Gross WL. Immunopathology of ANCA-associated vasculitis. Intern Med. 1999; 38:759–765.
   Google Scholar
• Jayne DR, Esnault VL, Lockwood CM. Anti-idiotype antibodies to anti-myeloperoxidase autoantibodies in patients with systemic vasculitis. J Autoimmun. 1993; 6:221–226.
   Google Scholar
• Strunz HP, Csernok E, Gross WL. Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7 Id) whose antiidiotype inhibits proteinase 3-antineutrophil cytoplasmic antibody antigen binding activity. Arthritis Rheum. 1997; 40:135–142.
   Google Scholar
• Pradhan VD, Ghosh K. Anti-idiotype antibodies in immune regulation of anca associated vasculitis. Indian J Dermatol. 2009; 54:258–262.
   Google Scholar
• Chen QY, Rowley MJ, Mackay IR. Anti-idiotypic antibodies to anti-PDC-E2 in primary biliary cirrhosis and normal subjects. Hepatology. 1999; 29:624–631.
   Google Scholar
• Dwyer DS, Bradley RJ, Urquhart CK, Kearney JF. Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature. 1983; 301:611–614.
   PubMed Web of Science ®Google Scholar
• Lefvert AK, Pirskanen R, Svanborg E. Anti-idiotypic antibodies, acetylcholine receptor antibodies and disturbed neuromuscular function in healthy relatives to patients with myasthenia gravis. J Neuroimmunol. 1985; 9:41–53.
   Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008; 8:22–33.
   PubMed Web of Science ®Google Scholar